Cantor Fitzgerald has a “Overweight” rating and a $790.00 price target on the stock. The consensus estimate for Meta Platforms’ current full-year earnings is $26.70 per share.

Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Research analysts at Cantor Fitzgerald cut their FY2025 earnings estimates for shares of Bradmer Pharmaceuticals in a note issued to ...

Cantor Fitzgerald says Tesla (TSLA) pre-announced that it delivered 336,681 vehicles in Q1, below the Bloomberg consensus of 377,590. Tesla also pre-announced that it had produced 362,615 vehicles ...

On Thursday, Cantor Fitzgerald maintained its Neutral rating on Acadia Healthcare (NASDAQ:ACHC) with a consistent price target of $40.00, as the stock trades near $29.21, close to its 52-week low.

Monday, Cantor Fitzgerald reiterated an Overweight rating on Moonlake Immunotherapeutics (NASDAQ: MLTX), a $2.4 billion market cap biotech company that appears undervalued according to InvestingPro ...

On Thursday, Cantor Fitzgerald maintained its Overweight rating on Tenet Healthcare shares with a price target of $177.00. The firm observed stable nursing trends within the company, but noted ...

On Thursday, Cantor Fitzgerald reiterated its Overweight rating on shares of Cytokinetics (NASDAQ:CYTK), with a focus on the company’s heart failure treatment, Afi™. While the stock is currently ...

(Reuters) - Cantor Fitzgerald analysts renewed their criticism of U.S. Health Secretary Robert F. Kennedy Jr. on Thursday, saying the layoffs at the Food and Drug Administration pose a risk to ...

Cantor Analysts Double Down on Kennedy Criticism as FDA Jobs Cuts Begin (Reuters) - Cantor Fitzgerald analysts renewed their criticism of U.S. Health Secretary Robert F. Kennedy Jr. on Thursday ...

Kylie is the Deputy Live Pages Editor, helping showcase Reuters multimedia coverage of the biggest global stories. She previously worked on the UK Breaking News team, and spent eight years in ...